secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001493152-24-009978
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx promotes Leesa Gentry to CCO; salary $325k, option for 190k shares
---------------------------------------------------------------------------

- Leesa Gentry promoted from SVP of Clinical Operations to Chief Clinical Officer, effective March 1, 2024.
- Annual base salary of $325,000, with potential increase to $396,000 if CEO salary restored after 2024 reduction.
- Eligible for annual discretionary bonus up to 35% of base salary; for 2024 bonus not pro-rated.
- Received option to purchase 190,000 shares at $1.69 per share, vesting over 4 years in monthly installments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/0001493152-24-009978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224009978/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer